Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06353386
Registration number
NCT06353386
Ethics application status
Date submitted
3/04/2024
Date registered
9/04/2024
Date last updated
30/05/2024
Titles & IDs
Public title
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Query!
Scientific title
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Query!
Secondary ID [1]
0
0
MK-5684-01A
Query!
Secondary ID [2]
0
0
5684-01A
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostatic Neoplasms, Castration-Resistant
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Opevesostat
Treatment: Drugs - Olaparib
Treatment: Drugs - Docetaxel
Treatment: Drugs - Cabazitaxel
Experimental: Arm A1: Opevesostat - Participants receive 5 mg of opevesostat twice daily via oral tablet until progressive disease or discontinuation.
Experimental: Arm A2: Olaparib + Opevesostat - Participants receive 5 mg of opevesostat twice daily via oral tablet PLUS 300 mg of olaparib twice daily via oral tablet until progressive disease or discontinuation.
Experimental: Arm A3: Docetaxel + Opevesostat - Participants receive 5 mg of opevesostat twice daily via oral tablet PLUS 75 mg/m^2 of docetaxel once every 3 weeks (Q3W) via IV infusion until progressive disease or discontinuation.
Experimental: Arm A4: Cabazitaxel + Opevesostat - Participants receive 5 mg of opevesostat twice daily via oral tablet PLUS 20 mg/m^2 of cabazitaxel once every 3 weeks (Q3W) via IV infusion until progressive disease or discontinuation.
Treatment: Drugs: Opevesostat
Oral Tablet
Treatment: Drugs: Olaparib
Oral Tablet
Treatment: Drugs: Docetaxel
IV Infusion
Treatment: Drugs: Cabazitaxel
IV Infusion
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants who experience one or more dose-limiting toxicities (DLTs)
Query!
Assessment method [1]
0
0
The following events, if considered drug related by the investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not laboratory value); Grade 4 hematologic toxicity lasting >7 days, except thrombocytopenia (Grade 4 thrombocytopenia of any duration, Grade 3 thrombocytopenia associated with clinically significant bleeding); Any nonhematologic adverse event (AE) >Grade 3 in severity should be considered a DLT (with exceptions); Any Grade 3 or Grade 4 nonhematologic laboratory value (if certain criteria are met); Febrile neutropenia Grade 3 or Grade 4; Prolonged delay (>2 weeks) in initiating treatment after the first 28 days due to study intervention-related toxicity; Missing >25% of study intervention doses as a result of drug-related AE(s) during the first 28 days; Grade 5 toxicity.
Query!
Timepoint [1]
0
0
Up to approximately 28 days
Query!
Primary outcome [2]
0
0
Number of participants who experience one or more adverse events (AEs)
Query!
Assessment method [2]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Query!
Timepoint [2]
0
0
Up to approximately 46 months
Query!
Primary outcome [3]
0
0
Number of participants who discontinue study intervention due to an AE
Query!
Assessment method [3]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Query!
Timepoint [3]
0
0
Up to approximately 46 months
Query!
Primary outcome [4]
0
0
Prostate-specific antigen (PSA) response rate
Query!
Assessment method [4]
0
0
The Prostate-specific Antigen (PSA) response rate is the percentage of participants who had PSA response defined as a reduction in the PSA level from baseline by =50%. The reduction in PSA level will be confirmed by an additional PSA evaluation performed =3 weeks from the original response per Prostate Cancer Working Group (PCWG) criteria.
Query!
Timepoint [4]
0
0
Up to approximately 46 months
Query!
Secondary outcome [1]
0
0
Objective response rate (ORR)
Query!
Assessment method [1]
0
0
The ORR is defined as the percentage of participants with complete response (CR: disappearance of all target lesions per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1); and no evidence of disease (NED) on base scan per Prostate Cancer Working Group (PCWG) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1; and non-progressive disease, non-evaluable [NE], or NED on bone scan or CR with non-progressive disease or NE bone scan per PCWG). ORR will be assessed by Blinded Independent Central Review (BICR).
Query!
Timepoint [1]
0
0
Up to approximately 46 months
Query!
Secondary outcome [2]
0
0
Radiographic progression-free survival (rPFS)
Query!
Assessment method [2]
0
0
rPFS is defined as the time from randomization to occurrence of: radiological tumor progression using RECIST 1.1 as assessed by BICR; progression of bone lesions using PCWG criteria; or death due to any cause. Progression as per modified RECIST 1.1 is =20% increase in the sum of diameters of target lesions and progression of existing non-target lesions. Progression of bone lesions by PCWG criteria is the appearance of =2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and are persistent for =6 weeks. rPFS will be assessed by BICR.
Query!
Timepoint [2]
0
0
Up to approximately 46 months
Query!
Secondary outcome [3]
0
0
Overall survival (OS)
Query!
Assessment method [3]
0
0
OS is defined as the time from randomization to death due to any cause.
Query!
Timepoint [3]
0
0
Up to approximately 46 months
Query!
Secondary outcome [4]
0
0
Duration of response (DOR)
Query!
Assessment method [4]
0
0
DOR is defined as the time from first documented evidence of complete response (CR) or partial response (PR) per PCWG and RECIST 1.1 criteria until progressive disease (PD) or death. PD per RECIST 1.1 is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of a least 5 mm. PD per PCWG is the appearance of >2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and are persistent for >6 weeks. DOR will be assessed by BICR.
Query!
Timepoint [4]
0
0
Up to approximately 46 months
Query!
Secondary outcome [5]
0
0
Time to first subsequent anticancer therapy (TFST)
Query!
Assessment method [5]
0
0
TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first.
Query!
Timepoint [5]
0
0
Up to approximately 46 months
Query!
Secondary outcome [6]
0
0
Time to pain progression (TTPP)
Query!
Assessment method [6]
0
0
TTPP is defined as the time from randomization to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" and by opiate analgesic use.
Query!
Timepoint [6]
0
0
Up to approximately 46 months
Query!
Eligibility
Key inclusion criteria
The main inclusion criteria include but are not limited to the following:
- Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
without small cell histology.
- Prostate cancer progression and received androgen deprivation therapy (ADT) or post
bilateral orchiectomy within 6 months before screening.
- Evidence of disease progression from either, >4 weeks from last flutamide treatment,
or >6 weeks from last bicalutamide or nilutamide treatment, if receiving first
generation anti-androgen therapy as last treatment therapy.
- Current evidence of metastatic disease.
- Prior treatment with 1 to 2 novel hormonal agent(s) (NHA) for non-metastatic, or
metastatic, hormone-sensitive prostate cancer or castration-resistant prostate cancer
and have disease progression during or after treatment.
- Treatment with bone resorptive therapy (including, but not limited to, bisphosphonate
or denosumab) must have been on stable doses for >4 weeks before randomization.
- Participants who experienced adverse events (AEs) due to previous anticancer therapies
must have recovered to <Grade 1 or baseline.
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV
on antiretroviral therapy.
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they
have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have
undetectable HBV viral load.
- Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV
viral load is undetectable.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
The main exclusion criteria include but are not limited to the following:
- History of pituitary dysfunction.
- Poorly controlled diabetes mellitus.
- Active or unstable cardio/cerebro-vascular disease, including thromboembolic events.
- History or family history of long corrected QT interval (QTc) syndrome.
- Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or features suggestive of
MDS/AML.
- History or current condition of adrenal insufficiency.
- History of (noninfectious) pneumonitis requiring steroids, or current pneumonitis.
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric
Castleman's Disease.
- Undergone major surgery, including local prostate intervention (except prostate
biopsy) within 28 days before randomization, and has not recovered from the toxicities
and/or complications.
- Is on an unstable dose of thyroid hormone therapy within 6 months prior to first dose
of study intervention.
- Received a whole blood transfusion in the last 120 days before randomization (packed
red blood cells and platelet transfusions are acceptable if not given within 28 days
before randomization).
- Received prior systemic anticancer therapy including investigational agents within 4
weeks before randomization.
- Received prior radiotherapy within 2 weeks of start of study intervention or
radiation-related toxicities, requiring corticosteroids.
- Received a live or live-attenuated vaccine within 30 days before the first does of
study intervention. Administration of killed vaccines is allowed.
- Diagnosis of immunodeficiency, or is receiving chronic systemic steroid therapy, or
any other form of immunosuppressive therapy, within 7 days prior to the first dose of
study intervention.
- Known additional malignancy that is progressing or has required active treatment
within the past 3 years.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Active autoimmune disease that has required systemic treatment in the past 2 years.
- Active infection requiring systemic therapy.
- Concurrent active HBV and HCV infections.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/05/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/03/2028
Query!
Actual
Query!
Sample size
Target
220
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0110) - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3000 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
Israel
Query!
State/province [1]
0
0
Haifa
Query!
Country [2]
0
0
Israel
Query!
State/province [2]
0
0
Petah Tikva
Query!
Country [3]
0
0
Taiwan
Query!
State/province [3]
0
0
Taichung
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Orion Corporation, Orion Pharma
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Substudy 01A is part of a larger research study that is testing experimental treatments for
metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella
study (U01).
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based
treatment combinations, or as a single agent, in participants with mCRPC.
This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety
lead-in phase will be used to evaluate the safety and tolerability, and to establish a
recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will
be no hypothesis testing in this study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06353386
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Toll Free Number
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-888-577-8839
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06353386
Download to PDF